JP2009501776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009501776A5 JP2009501776A5 JP2008522065A JP2008522065A JP2009501776A5 JP 2009501776 A5 JP2009501776 A5 JP 2009501776A5 JP 2008522065 A JP2008522065 A JP 2008522065A JP 2008522065 A JP2008522065 A JP 2008522065A JP 2009501776 A5 JP2009501776 A5 JP 2009501776A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- compound
- formula
- benzyl
- free fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 235000021588 free fatty acids Nutrition 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 230000010261 cell growth Effects 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 239000003085 diluting agent Substances 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 201000008980 hyperinsulinism Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 238000012360 testing method Methods 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- MGJFLAHLODASKL-UHFFFAOYSA-N 2-(4-chloroanilino)-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound FC(F)(F)C1=CC=CC(CC2C(N=C(NC=3C=CC(Cl)=CC=3)S2)=O)=C1 MGJFLAHLODASKL-UHFFFAOYSA-N 0.000 claims 2
- LKJFEVJLZCHMNR-UHFFFAOYSA-N 2-(4-methylanilino)-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound C1=CC(C)=CC=C1NC(S1)=NC(=O)C1CC1=CC=CC(C(F)(F)F)=C1 LKJFEVJLZCHMNR-UHFFFAOYSA-N 0.000 claims 2
- -1 5- [3- (trifluoromethyl) benzyl] -4-oxothiazolidine-2-yl Phenyl Chemical group 0.000 claims 2
- OJOXIPILLXOGHW-UHFFFAOYSA-N 5-[(4-fluorophenyl)methyl]-2-(pyridin-2-ylamino)-1,3-thiazol-4-one Chemical compound C1=CC(F)=CC=C1CC1C(=O)N=C(NC=2N=CC=CC=2)S1 OJOXIPILLXOGHW-UHFFFAOYSA-N 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 claims 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 claims 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- MEEOKGMAKDGKDE-UHFFFAOYSA-N 2-(2,4-dichloroanilino)-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound FC(F)(F)C1=CC=CC(CC2C(NC(S2)=NC=2C(=CC(Cl)=CC=2)Cl)=O)=C1 MEEOKGMAKDGKDE-UHFFFAOYSA-N 0.000 claims 1
- XCZIHERGIOEZRO-UHFFFAOYSA-N 2-(3,4-dichloroanilino)-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound FC(F)(F)C1=CC=CC(CC2C(NC(S2)=NC=2C=C(Cl)C(Cl)=CC=2)=O)=C1 XCZIHERGIOEZRO-UHFFFAOYSA-N 0.000 claims 1
- LCBASURTTNEAPL-UHFFFAOYSA-N 2-(4-chloroanilino)-5-[(4-methylphenyl)methyl]-1,3-thiazol-4-one Chemical compound C1=CC(C)=CC=C1CC1C(=O)N=C(NC=2C=CC(Cl)=CC=2)S1 LCBASURTTNEAPL-UHFFFAOYSA-N 0.000 claims 1
- CYCZYGRIZJUNBZ-UHFFFAOYSA-N 2-(4-methoxyanilino)-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound C1=CC(OC)=CC=C1N=C1SC(CC=2C=C(C=CC=2)C(F)(F)F)C(=O)N1 CYCZYGRIZJUNBZ-UHFFFAOYSA-N 0.000 claims 1
- ACQMGTBEKGXGJU-UHFFFAOYSA-N 2-(4-propan-2-ylanilino)-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound C1=CC(C(C)C)=CC=C1N=C1SC(CC=2C=C(C=CC=2)C(F)(F)F)C(=O)N1 ACQMGTBEKGXGJU-UHFFFAOYSA-N 0.000 claims 1
- DXTMCFZBFJNDOP-UHFFFAOYSA-N 2-anilino-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-4-one Chemical compound FC(F)(F)C1=CC=CC(CC2C(N=C(NC=3C=CC=CC=3)S2)=O)=C1 DXTMCFZBFJNDOP-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- GWTUAJSBEZTXJX-UHFFFAOYSA-N 3-methyl-2-(4-methylphenyl)imino-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazolidin-4-one Chemical compound S1C(=NC=2C=CC(C)=CC=2)N(C)C(=O)C1CC1=CC=CC(C(F)(F)F)=C1 GWTUAJSBEZTXJX-UHFFFAOYSA-N 0.000 claims 1
- BLDISNZVRORTLZ-UHFFFAOYSA-N 4-[[[4-(2-hydroxyphenyl)-5-[(2-methoxyphenyl)methyl]-1,3-thiazol-2-yl]amino]methyl]benzoic acid Chemical compound COC1=CC=CC=C1CC1=C(C=2C(=CC=CC=2)O)N=C(NCC=2C=CC(=CC=2)C(O)=O)S1 BLDISNZVRORTLZ-UHFFFAOYSA-N 0.000 claims 1
- XADDQYPFOIKDIZ-UHFFFAOYSA-N 4-[[[5-[(2,3-difluorophenyl)methyl]-4-(2-hydroxyphenyl)-1,3-thiazol-2-yl]amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNC(S1)=NC(C=2C(=CC=CC=2)O)=C1CC1=CC=CC(F)=C1F XADDQYPFOIKDIZ-UHFFFAOYSA-N 0.000 claims 1
- SCQQRZGNOYUJMM-UHFFFAOYSA-N 4-[[[5-[(2,6-difluorophenyl)methyl]-4-(2-hydroxyphenyl)-1,3-thiazol-2-yl]amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNC(S1)=NC(C=2C(=CC=CC=2)O)=C1CC1=C(F)C=CC=C1F SCQQRZGNOYUJMM-UHFFFAOYSA-N 0.000 claims 1
- ZRQDEHTUTQHZPU-UHFFFAOYSA-N 4-[[[5-[(2,6-difluorophenyl)methyl]-4-(3-hydroxyphenyl)-1,3-thiazol-2-yl]amino]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CNC(S1)=NC(C=2C=C(O)C=CC=2)=C1CC1=C(F)C=CC=C1F ZRQDEHTUTQHZPU-UHFFFAOYSA-N 0.000 claims 1
- KXPAJSAIUIKHHH-UHFFFAOYSA-N 4-chloro-n-[4-oxo-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]benzamide Chemical compound FC(F)(F)C1=CC=CC(CC2C(NC(S2)=NC(=O)C=2C=CC(Cl)=CC=2)=O)=C1 KXPAJSAIUIKHHH-UHFFFAOYSA-N 0.000 claims 1
- HVTYXFRFLWCHNY-UHFFFAOYSA-N 4-chloro-n-[4-oxo-5-[[3-(trifluoromethyl)phenyl]methyl]-1,3-thiazol-2-yl]benzenesulfonamide Chemical compound FC(F)(F)C1=CC=CC(CC2C(NC(S2)=NS(=O)(=O)C=2C=CC(Cl)=CC=2)=O)=C1 HVTYXFRFLWCHNY-UHFFFAOYSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108010011459 Exenatide Proteins 0.000 claims 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940126033 PPAR agonist Drugs 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 229940104230 thymidine Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59562005P | 2005-07-21 | 2005-07-21 | |
| SE0501721 | 2005-07-21 | ||
| US74442206P | 2006-04-07 | 2006-04-07 | |
| PCT/GB2006/002743 WO2007010281A2 (en) | 2005-07-21 | 2006-07-21 | Use of thiazole derivatives and analogues in disorders caused by free fatty acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009501776A JP2009501776A (ja) | 2009-01-22 |
| JP2009501776A5 true JP2009501776A5 (US07476746-20090113-C00133.png) | 2009-09-10 |
Family
ID=37669179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522062A Withdrawn JP2009501775A (ja) | 2005-07-21 | 2006-07-21 | 癌治療におけるチアゾール誘導体およびアナログの使用 |
| JP2008522065A Withdrawn JP2009501776A (ja) | 2005-07-21 | 2006-07-21 | 遊離脂肪酸に起因した障害におけるチアゾール誘導体およびアナログの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008522062A Withdrawn JP2009501775A (ja) | 2005-07-21 | 2006-07-21 | 癌治療におけるチアゾール誘導体およびアナログの使用 |
Country Status (10)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005024012A1 (de) * | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Verwendung von 2,5-disubstituierten Thiazol-4-on-Derivaten in Arzneimitteln |
| WO2008065409A2 (en) * | 2006-12-01 | 2008-06-05 | Betagenon Ab | Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor |
| WO2008090327A1 (en) * | 2007-01-22 | 2008-07-31 | Betagenon Ab | New combination for use in the treatment of cancer |
| US20080234332A1 (en) * | 2007-03-20 | 2008-09-25 | Xiong Cai | Raf kinase inhibitors containing a zinc binding moiety |
| CN101274918A (zh) * | 2007-03-30 | 2008-10-01 | 中国科学院上海药物研究所 | 一类取代五元杂环化合物,其制备方法和医学用途 |
| WO2009019445A1 (en) * | 2007-08-03 | 2009-02-12 | Betagenon Ab | Dithiazolidine and thiazolidine derivatives as anticancer agents |
| BRPI0818658A2 (pt) | 2007-10-09 | 2015-04-14 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de piridina úteis como ativadores de glicoquinase |
| US20110263664A1 (en) * | 2007-11-15 | 2011-10-27 | Musc Foundation For Research Development | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer |
| KR100998572B1 (ko) * | 2007-12-14 | 2010-12-07 | 한국생명공학연구원 | 단백질 포스파타제의 활성을 억제하는 페닐아미노티아졸론유도체 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 암 예방 및 치료용 조성물 |
| WO2010073011A2 (en) | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
| WO2010086613A1 (en) | 2009-01-30 | 2010-08-05 | Betagenon Ab | Compounds useful as inhibitors as ampk |
| HUE027263T2 (en) | 2009-07-08 | 2016-10-28 | Baltic Bio Ab | 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer |
| WO2011079036A1 (en) * | 2009-12-22 | 2011-06-30 | The Translational Genomics Research Institute | Benzamide derivatives |
| WO2012118935A1 (en) | 2011-03-03 | 2012-09-07 | Proteotech Inc | Compounds for the treatment of neurodegenerative diseases |
| US8722670B2 (en) * | 2011-09-30 | 2014-05-13 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| WO2013108026A1 (en) | 2012-01-17 | 2013-07-25 | Baltic Bio Ab | Thiadiazolone derivatives useful in the treatment of diabetes |
| CN104059060B (zh) * | 2014-05-30 | 2017-08-01 | 西安交通大学 | 一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3345374A (en) * | 1962-09-04 | 1967-10-03 | Bayer Ag | Certain oxathiazole and dithiazole derivatives |
| US3671537A (en) * | 1969-06-05 | 1972-06-20 | Gyogyszerkutato Intezet | Certain 3-(2,6-dichlorophenyl)-2-iminothiazolidines |
| US4103018A (en) * | 1976-10-12 | 1978-07-25 | Schering Corporation | 2-[4-(Polyhalo-2-hydroxy-2-propyl)anilino]-2-oxazolin-4-ones and thiazolin-4-ones corresponding thereto |
| HU191408B (en) * | 1984-04-25 | 1987-02-27 | Egis Gyogyszergyar,Hu | Process for preparing new imino-thiazolidine derivatives |
| DD246541A1 (de) * | 1986-01-27 | 1987-06-10 | Univ Halle Wittenberg | Verfahren zur herstellung von 5-arylidenthiazolidin-4-onen |
| DD270072A1 (de) * | 1988-03-14 | 1989-07-19 | Univ Halle Wittenberg | Verfahren zur herstellung von 5-aryliden- hoch 2-thiazolin-4-onen |
| US6353006B1 (en) * | 1999-01-14 | 2002-03-05 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| AU2003282980A1 (en) * | 2002-10-23 | 2004-05-13 | Beyond Genomics, Inc. | 4-alkenylthiazoles comprising epoxide functionality, and methods of use thereof |
| WO2005082363A1 (en) * | 2004-02-20 | 2005-09-09 | Board Of Regents, The University Of Texas System | Thiazolone compounds for treatment of cancer |
| MXPA06012504A (es) * | 2004-04-30 | 2006-12-15 | Schering Corp | Moduladores del receptor neuropeptido. |
| CN1984909A (zh) * | 2004-07-01 | 2007-06-20 | 霍夫曼-拉罗奇有限公司 | 噻唑啉酮未取代的喹啉 |
| MX2007001539A (es) * | 2004-08-10 | 2007-04-23 | Exelisis Inc | Compuestos heterociclicos como agentes farmaceuticos. |
| KR100890533B1 (ko) * | 2004-10-14 | 2009-03-27 | 에프. 호프만-라 로슈 아게 | Ｃｄｋ1 저해제로서의 퀴나졸리닐메틸렌 티아졸리논 |
| CN100525929C (zh) * | 2005-04-20 | 2009-08-12 | 郭文礼 | 喷水枪出水控制装置 |
| CA2614098A1 (en) * | 2005-07-04 | 2007-01-11 | Dr. Reddy's Laboratories Ltd. | Thiazoles derivatives as ampk activator |
-
2006
- 2006-07-21 EA EA200800302A patent/EA200800302A1/ru unknown
- 2006-07-21 AU AU2006271383A patent/AU2006271383A1/en not_active Abandoned
- 2006-07-21 KR KR1020087001175A patent/KR20080032096A/ko not_active Application Discontinuation
- 2006-07-21 AU AU2006271375A patent/AU2006271375A1/en not_active Abandoned
- 2006-07-21 EP EP06765072A patent/EP1906956A2/en not_active Withdrawn
- 2006-07-21 CA CA002615752A patent/CA2615752A1/en not_active Abandoned
- 2006-07-21 EA EA200800303A patent/EA200800303A1/ru unknown
- 2006-07-21 EP EP06765059A patent/EP1906955A2/en not_active Withdrawn
- 2006-07-21 CA CA002614327A patent/CA2614327A1/en not_active Abandoned
- 2006-07-21 WO PCT/GB2006/002730 patent/WO2007010273A2/en active Application Filing
- 2006-07-21 US US11/989,029 patent/US20090156644A1/en not_active Abandoned
- 2006-07-21 KR KR1020087001174A patent/KR20080034436A/ko not_active Application Discontinuation
- 2006-07-21 US US11/989,001 patent/US20090136472A1/en not_active Abandoned
- 2006-07-21 WO PCT/GB2006/002743 patent/WO2007010281A2/en active Application Filing
- 2006-07-21 JP JP2008522062A patent/JP2009501775A/ja not_active Withdrawn
- 2006-07-21 JP JP2008522065A patent/JP2009501776A/ja not_active Withdrawn
-
2007
- 2007-12-10 IL IL188031A patent/IL188031A0/en unknown
- 2007-12-11 NO NO20076333A patent/NO20076333L/no not_active Application Discontinuation
- 2007-12-13 NO NO20076420A patent/NO20076420L/no not_active Application Discontinuation
- 2007-12-16 IL IL188163A patent/IL188163A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009501776A5 (US07476746-20090113-C00133.png) | ||
| JP2009501775A5 (US07476746-20090113-C00133.png) | ||
| DK2038265T3 (en) | Inhibitors of human protein tyrosine phosphatase and methods of use | |
| AU754488B2 (en) | Method for treating diabetes employing an aP2 inhibitor and combination | |
| JP2009504599A (ja) | Ｄｐｐ−ｉｖ阻害剤を含有する医薬組成物 | |
| CN1829511A (zh) | 血管紧张素ⅱ受体拮抗剂,特别是泰米沙坦用于提高胰岛素敏感性的用途 | |
| WO2008022267A2 (en) | Combination treatment for metabolic disorders | |
| ZA200406068B (en) | Thiazole and oxazole derivatives which modulate PPAR activity. | |
| US20180117013A1 (en) | Methods of treating liver disease using indane acetic acid derivatives | |
| MXPA05009789A (es) | Combinacion de un antagonista del receptor de aldosterona y un agente antidiabetico. | |
| JP2006516251A5 (US07476746-20090113-C00133.png) | ||
| US20110092517A1 (en) | Use of PPAR Delta Ligands for the Treatment or Prevention of Inflammation or Energy Metabolism/Production Related Diseases | |
| JP5968927B2 (ja) | 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用 | |
| JP2000273043A (ja) | ピオグリタゾンを含有する耐糖能不全治療剤 | |
| CN101878030A (zh) | 用于治疗免疫性和炎性疾病和病症的组合物和方法 | |
| JP2007538102A5 (US07476746-20090113-C00133.png) | ||
| CN107074838A (zh) | 具有gpr119激动剂活性的化合物、制备其的方法和包含其作为有效组分的药物组合物 | |
| CA2588571A1 (en) | Insulin secretagogue drugs | |
| BG103966A (bg) | Лечение на диабет с тиазолидиндион и инхибитор наалфа глюкозидазата | |
| CN1167416C (zh) | 利用葡萄糖摄入增强剂制备减小心脏缺血后损伤的药物 | |
| JP2005514399A (ja) | ＰＰＡＲγアクチベーターの投薬法 | |
| JP2003063993A (ja) | 医薬組成物 | |
| CN102949406A (zh) | 一种复方艾夫他滨药物组合物及其制备方法和用途 | |
| KR100697097B1 (ko) | 당뇨병 예방 또는 치료용 약학 조성물 | |
| KR19990036290A (ko) | 비인슐린 의존성 진성 당뇨병 환자에 대한 외인성 인슐린 투여량의 감소 방법 |
